MBNL1 and myotonic dystrophy type 1: Efforts to treat DM1 by reducing the synthesis of CUGexp RNA, accelerating its decay, blocking its interactions with binding proteins, or increasing the expression of Mbnl have all shown benefit in animal models, suggesting that RNA dominant mechanisms are unusually tractable for therapeutic intervention (reviewed in reference (18)).